Cargando…

P1262: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH FLT3–INTERNAL TANDEM DUPLICATION MUTATION

Detalles Bibliográficos
Autores principales:	Liang, Chen, He, Yi, Pang, Aiming, Yang, Donglin, Zhang, Rongli, Zhai, Weihua, Wu, Xiaojin, Feng, Sizhou, Han, Mingzhe, Jiang, Erlie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430485/ http://dx.doi.org/10.1097/01.HS9.0000971936.49346.c4

Ejemplares similares

The prognostic impact of previously infectious complications on allogeneic hematopoietic stem cell transplantation for patients with severe aplastic anemia: A single-center, retrospective study
por: Zhang, Yuanfeng, et al.
Publicado: (2022)

Comparison of characteristics and outcomes on ETP-ALL/LBL and non-ETP ALL patients receiving allogeneic hematopoietic stem cell transplantation
por: Chen, Juan, et al.
Publicado: (2023)

Cardiac involvement in a patient with B-cell lymphoblastic lymphoma/acute lymphoblastic leukemia and a history of allogeneic hematopoietic stem cell transplantation and CAR T-cell therapy: A case report
por: Cao, Yigeng, et al.
Publicado: (2023)

Risk factors associated with hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation
por: Shen, Biao, et al.
Publicado: (2022)

The outcome of acute leukemia patients with SET-NUP214 fusion after allogeneic stem cell transplantation
por: Shen, Yuyan, et al.
Publicado: (2023)

Combination treatment of rituximab and donor platelets infusion to reduce donor‐specific anti‐HLA antibodies for stem cells engraftment in haploidentical transplantation
por: Zhang, Rongli, et al.
Publicado: (2020)

Efficacy of Recombinant Human Thrombopoietin for the Treatment of Secondary Failure of Platelet Recovery After Allogeneic HSCT
por: Cao, Yigeng, et al.
Publicado: (2022)

P575: GILTERITINIB MAINTENANCE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR FLT3 MUTATED ACUTE MYELOID LEUKEMIA
por: Žučenka, Andrius, et al.
Publicado: (2023)

Comparison of porcine ALG and rabbit ATG on outcomes of HLA-haploidentical hematopoietic stem cell transplantation for patients with acquired aplastic anemia
por: Chen, Juan, et al.
Publicado: (2022)

Intravenous-oral itraconazole versus oral posaconazole in preventing invasive fungal diseases for acute leukemia patients
por: Liu, Li, et al.
Publicado: (2023)

Optimizing autologous hematopoietic stem cell transplantation for acute leukemia
por: Pang, Aiming, et al.
Publicado: (2021)

Comparison of Hematopoietic Stem Cell Transplantation Outcomes Using Matched Sibling Donors, Haploidentical Donors, and Immunosuppressive Therapy for Patients With Acquired Aplastic Anemia
por: Zhang, Yuanfeng, et al.
Publicado: (2022)

Mucosal-associated invariant T cells predict increased acute graft-versus-host-disease incidence in patients receiving allogeneic hematopoietic stem cell transplantation
por: Wang, Zhao, et al.
Publicado: (2022)

P1273: COMPARISON OF TOTAL BODY IRRADIATION-BASED WITH CHEMOTHERAPY-BASED MYELOABLATIVE CONDITIONING REGIMENS IN PATIENTS WITH B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST COMPLETE REMISSION
por: Mengnan, LV, et al.
Publicado: (2023)

PB1731: INOTUZUMAB OZOGAMICIN IN LYMPHOID B-CELL MALIGNANCY：A SINGLE CENTER ANALYSIS IN THE REAL WORLD
por: LV, Mengnan, et al.
Publicado: (2023)

Retrospective Comparison of Efficacy and Safety of Rabbit Anti-Thymocyte Globulin and Porcine Anti-Lymphocyte Globulin in Patients With Acquired Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation From Matched Sibling Donors
por: Zhang, Yuanfeng, et al.
Publicado: (2022)

Hematopoietic stem cell transplantation from an infected SARS-CoV2 haploidentical donor: A case report
por: Chen, Xin, et al.
Publicado: (2023)

Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3‐internal tandem duplication AML: The JALSG AML209‐FLT3‐SCT study
por: Kawashima, Naomi, et al.
Publicado: (2020)

Outcome of autologous stem cell transplantation in patients with favorable-risk acute myeloid leukemia in first remission
por: Chen, Juan, et al.
Publicado: (2022)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

Risk factors for CMV infection within 100 days posttransplantation in patients with acute leukemia
por: Chen, Juan, et al.
Publicado: (2022)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
por: Iannotta, R., et al.
Publicado: (2022)

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

P1290: UPFRONT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CAN PROVIDE SURVIVAL BENEFIT VERSUS HYPOMETHYLATING AGENT IN MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS I (MDS-IBI)
por: Runzhi, MA, et al.
Publicado: (2023)

Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
por: James, Angela Joubert, et al.
Publicado: (2020)

Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3(mut) AML
por: Terao, Toshiki, et al.
Publicado: (2022)

Gilteritinib as Bridging and Posttransplant Maintenance for Relapsed Acute Myeloid Leukemia with FLT3-ITD Mutation Accompanied by Extramedullary Disease in Elderly
por: Saburi, Masuho, et al.
Publicado: (2023)

P1308: RUXOLITINIB AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN APLASTIC ANEMIA PATIENTS
por: Zhang, Xiaoyu, et al.
Publicado: (2023)

CD11c participates in triggering acute graft‐versus‐host disease during bone marrow transplantation
por: Wang, Qianqian, et al.
Publicado: (2021)

Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation presenting as pericardial effusion
por: Shen, Yuyan, et al.
Publicado: (2023)

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia
por: Maziarz, Richard T., et al.
Publicado: (2020)

PB2452: PREVALENCE AND SEVERITY OF COVID-19 IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS IN CHINA
por: Gao, Hongye, et al.
Publicado: (2023)

Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation
por: Chew, Serena, et al.
Publicado: (2020)

Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia
por: Marjoncu, Dennis, et al.
Publicado: (2020)

Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
por: James, Angela Joubert, et al.
Publicado: (2021)

Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia
por: McCall, David, et al.
Publicado: (2021)

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
por: Daver, Naval, et al.
Publicado: (2022)

Cost-effectiveness of gilteritinib for relapsed/refractory FLT3(mut+) acute myeloid leukemia
por: Pandya, Bhavik J, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pl2qv0865do8o6j3bokd5hrkuu